Oculis Holding’s Promising Pipeline and Strategic Initiatives Drive Buy Rating

Oculis Holding (OCS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yi Chen from H.C. Wainwright reiterated a Buy rating on the stock and has a $32.00 price target.

Yi Chen’s rating is based on several promising developments within Oculis Holding. The company is advancing its pipeline with significant clinical milestones, including the ongoing Phase 3 trials of OCS-01 for diabetic macular edema (DME), which are expected to yield topline data in the second quarter of 2026. Additionally, the potential initiation of a Phase 2/3 trial for licaminlimab in dry eye disease and a registrational trial for privosegtor in acute optic neuritis are anticipated to further bolster the company’s prospects.
Moreover, Oculis has reported positive data from the Phase 2 ACUITY trial of privosegtor in acute optic neuritis, demonstrating both safety and efficacy. The company plans to engage with the FDA to discuss these results and the design of a registrational trial. Furthermore, Oculis is exploring the expansion of privosegtor’s application into other areas such as multiple sclerosis relapse and non-arteritic anterior ischemic optic neuropathy, both of which present significant unmet medical needs. These strategic initiatives and the potential of OCS-01 to transform the treatment paradigm for DME contribute to Yi Chen’s Buy rating.

According to TipRanks, Chen is an analyst with an average return of -16.4% and a 29.18% success rate. Chen covers the Healthcare sector, focusing on stocks such as Opko Health, Vivani Medical, and OKYO Pharma Limited Sponsored ADR.

In another report released on May 9, Stifel Nicolaus also maintained a Buy rating on the stock with a $35.00 price target.